Evaluating the effects of stopping ixekizumab treatment in plaque psoriasis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the outcomes of patients with moderate to severe plaque psoriasis who discontinue a short course of ixekizumab treatment. The study aims to assess the clinical course, relapse rates, and quality of life over two years following treatment withdrawal. Additionally, it seeks to identify genomic and immunomic signatures in skin biopsies and blood samples to understand the factors contributing to sustained good outcomes. The trial will compare these signatures between patients who maintain improvement and those who experience relapse.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (\>21-year-old).
* Diagnosed by dermatologist as plague-type PsO.
* Having moderate to severe plague-type PsO as defined by the following:
* Psoriasis Area and Severity Index (PASI) ≥12/72,
* And, investigator Global Assessment Score (IGA) ≥3,
* And, PsO involving body surface area involvement (BSA) ≥10%
* And Candidate for phototherapy and/or systemic therapy
* Topical corticosteroid up to moderate potencies are allowed
* Able to provide informed consent.

Exclusion Criteria:

* Forms of PsO other than plaque-type.
* Evidence of skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluation of the effect of the investigational product on PsO.
* Evidence of active tuberculosis or other active infections (like Hepatitis C/B), malignancy; active or known use of other immunosuppressive drugs (eg. AIDS, rheumatoid arthritis, organ rejection etc) at the screening visit.
* Previous exposure to any systemic immunosuppressants (eg. methotrexate) or phototherapy
* History or current signs of a severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
* Having current or history of malignancy, except non-melanoma skin cancer, within the previous 5 years that have been adequately treated.
* History of inflammatory bowel disease.
* Pregnancy or lactating mothers.
* As treatment regimen is different, participants with evidence of PsA will be excluded

Where it's running

• Singapore General Hospital
  Outram Park, Singapore Recruiting

Study contacts

• Principal investigator: Ying Ying Leung, MD — Singapore General Hospital
• Study coordinator: Ying Ying Leung, MD
• Email: katy.leung.y.y@singhealth.com.sg
• Phone: +65 63265276

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ixekizumab biosimilar SB35 vs Taltz: a single-dose PK and safety check in healthy adults

  This study tests whether the biosimilar SB35 behaves the same as Taltz in how the drug acts in the body and how well it is tolerated in healthy adults.

  Recruiting at 3 sites Phase 1 Samsung Bioepis Co., Ltd. · Busan, Busan and 2 other locations · NCT07789964

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Long-term ORKA-001 treatment for adults with plaque psoriasis

  This open-label extension will try ORKA-001 long-term in adults with moderate-to-severe plaque psoriasis who completed a previous ORKA-001 study.

  Recruiting at 39 sites Phase 2 Oruka Therapeutics, Inc. · Phoenix, Arizona and 38 other locations · NCT07449702

• D-2570 oral treatment for adults with moderate to severe plaque psoriasis

  This trial tests whether the oral medicine D-2570 helps adults with moderate to severe plaque psoriasis compared with placebo and an approved oral drug.

  Recruiting Phase 3 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07326813

• ICP-332 versus placebo for moderate-to-severe plaque psoriasis

  This will test whether ICP-332 helps adults with moderate-to-severe plaque psoriasis compared with a placebo.

  Recruiting Phase 2 Beijing InnoCare Pharma Tech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07251998

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.